# Data Integrity Issues in Dissolution Testing

Umesh V. Banakar, PhD

Professor and President Banakar Consulting Services Carmel, IN 46032 USA

Rajashree Gude, MPharm Assoc. Professor Goa College of Pharmacy Panaji, Goa INDIA

Presented at

SPDS 5<sup>th</sup> Annual Intl. Conf. Mumbai, Maharashtra INDIA

June 09, 2017

# DRUG DEVELOPMENT PROCESS OVERVIEW

- Drug Discovery
- Screening
- Pre-Clinical Testing
- IND Application
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- New Drug Application (NDA) / Biologics License Application (BLA)
- Phase IV and Beyond












	θ	000	D	E	III FEI	0	and the same	and the	-3	
25	RESULTS		3.0				% Di	psyloge		
26				Vessel Ma.						
27	Time	1	2	5.8	4	5	. 6	7.		1.5
20	10	19.81	19.78	20.18	19.64	19.62	19.63	10.09	20.14	19
29	20	29.37	31.24	31.78	29.95	30.67	30.13	30.79	29.37	31:
30	30 40	55.32	54.41	54.81	53.61	54.41	53.67	54.16	53.42	64
31	40	72.5t	75.22	73.53	74.04	72.96	75.42	73.51	74.66	75
32	50	89.55	86.70	85.84	87.67	85.34	87.94	90.29	89.50	87.
33	60	93.18	94.87	94.30	95.46	96.30	84.47	94.43	94.58	94
38										
英			% Dissolve	rd			100			
36	Time	Mean	Std Day	WESD			¥ 100	100	1900	
37	10	19.63	0.44	2.24			\$ 60	32		
38	20	30.40	0.94	3.08			E 40	100		
39	30	53.95	0.72	1.34			2 20	1000	100	
401	40	74.02	1.21	1.63			1000.00		-	
41.	50	87.76	1.80	1.83					8 50 50	
12	60	94.43	0.87	0.90				Time		
63										

Time	Cumulative Percentage Release									
(min)	F1	F2	F3	F4	F5	F6				
0	0	0	0	0	0	0				
5	38.04	41.46	57.38	20.85	26.67	34.49				
10	77.21	79.51	89.84	41.43	61.95	93.55				
15	91.79	93.65	99.68	58.32	94.28	100.7				









# Results

Output

	35204	25148	35279	15298	1952)	. S5648.	15770	35890	36022	36347
18.90135	1104	4590	4279	4800	ASST	4538	6090	4680	4821	4158
18,512	4000	4188	4277	4258	4396	4561	4553	4851	4835	4906
1832367	4120	4168	4268	4257	4280	4399	4674	4656	4853	4534
18.93333	1200	4190	4275	4179	4402	4599	6543	4653	4915	4906
18.944	4109	4199	4262	4290	4570	4588	6571	4645	4820	4958
18.95467	4126	4164	4245	4275	4376	4565	4639	4660	4827	A326
18.96533	4161	4175	4256	65125	4797	4577	8567	4575	4520	4527
18.976	6164	\$200	4286	6397	4408	4582	8548	4631	6824	8952
18.98887	4119	4209	4280	4901	8422	4600	4547	4897	4821	4955
18:99133	4145	4212	4363	4330	8450	4575	4730	4693	4854	4992
19.008	#185	4211	4301	6351	8586	4620	6725	4728	8922	5015
1931867	4236	4265	4817	4368	8584	4664	6781	4794	1990	5091
15/12/33	4250	4323	4407	4423	45.75	4729	4949	4862	5046	8173
11.04	4333	4376	4467	4601	4619	4836	4931	4543	1536	5359
19.05007	6511	8692	8561	6620	4701	899 t.	5048	5563	5272	5356
19:00:110	41/20	4160	4875	intro-	8886	5038	5208	5196	3.09	5530
19,077	4685	4733	4856	4885	4999	5258	5405	5370-	5617	8057
19-06167	4855	4912	5043	5905	5296	5454	5607	5613	1841	6000
19.09333	5089	5150	5253	5313	3666	5687	5952	5896	6857	6331
19.156	5293	5100	5495	1078	3881	1098	6142	6261	60.73	delte
19.33462	8505	5653	5346	8891	6013	6276	6467	6573	6896	7107
15,86133	1055	3084	3257	3055	3305	3473	3529	3477	1621	3097
19,870	2190	3062	3261	5340	5525	3504	2511	3991	5621	5679
1538/57	1369	3180	1217	1016	3299	2487	2509	0461	3623	3678
19.49333	1157	3200	3227	3349	8271	3429	3451	1446	1596	3674

### .... Data is data ....

Data is data ......

Data is data ......

Data is data ......


### THEN WHAT ....

Of course,

- INSPECTION
- AUDIT
- REVIEW
- DATA SOURCE VERIFICATION
- Integrity !!!!!

#### The most watched nations in FDA inspections $^{5}$





Top 10 Most cited deficiency groups 2016

Ranking	Groups	Critical	Others	
1	Quality System	38	449	772
2	Sterility Assurance	34	190	162
3	Production	20	191	543
4	Complaints and Recall	11	80	110
5	5 Qualification/Validation		123	232
6 7	Premises & Equipment	9	113	464
	Computerised Systems	9	44	120
8	8 Personnel		42	150
9	Documentation	2	166	646
10	Quality Control	2	42	192

# U.S. FDA

Current expectations and guidance, including data integrity and compliance with cGMP

CDER March 30, 2017

### Time to Revisit Fundamentals ....

- Data
- Integrity
- Data Source Verification
- Data Integrity

#### .... DATA ....

Information, especially facts or numbers, collected to be examined and considered and used to help decision-making, or information in an electronic form that can be stored and used by a computer

Distinct information that is formatted in a special way. **Data** exists in a variety of forms, like text on paper or bytes stored in electronic memory

Dictionar(ies) ....

### Integrity ....

APPROVING the <u>quality</u> of being <u>honest</u> and having strong <u>moral principles</u> that you <u>refuse</u> to <u>change</u>

Cambridge Oxford Dictionary, 2016

### **Verification**

The act or process of confirming or checking the accuracy of:

- the state of being confirmed, or
- having the accuracy of checked.

Webster Dictionary, 2015

### **Data Source Verification**

The process by which *data* within the case report form (CRF) or other *data* collection systems are compared to the original *source* of information (and vice versa)

Medical Dictionary, 2014

### **Data Integrity**

Data integrity is the maintenance of, and the assurance of the accuracy and consistency of, data over its entire life-cycle, and is a critical aspect to the design, implementation and usage of any system which stores, processes, or retrieves data.

Business Dictionary, 2016; Wikipedia 2016

#### What is **DATA INTEGRITY**

Data integrity refers to the completeness, consistency, and accuracy of data.

Complete, consistent, and accurate data should be attributable, legible, contemporaneously recorded, original or a true copy, and accurate (ALCOA).

US FDA Guidance, April 2016; EMA; WHO 2015

### DI - Not a New Concept ....

Principles from the paper-and-ink era still apply:

- § 211.68 requires that backup data are exact and complete, and secure from alteration, inadvertent erasures, or loss
- § 212.110(b) requires that data be stored to prevent deterioration or loss
- §§ 211.100 and 211.160 require that certain activities be documented at the time of performance and that laboratory controls be scientifically sound
- § 211.180 requires true copies or other accurate reproductions of the original records; and
- §§ 211.188, 211.194, and 212.60(g) require complete information, complete data derived from all tests, complete record of all data, and complete records of all tests performed.

US FDA 2016 (post Publn. Draft Guidance)

# Noncompliances not confined to Falsification and Fraud

The main data integrity issues concern poor data management [95%] and falsification and fraud [5%]!!

# Data Integrity *GLOBAL ISSUE !!*

Noncompliances from the EMA, Warning Letters from the US-FDA, Canada, the UK and Italy as well as China and India.

It is not just a problem for Asia — it is a Global Issue!!

# Data Integrity Non-compliance issues

### Potential causes/reasons (not limited to) ....

- Poor communication (written/oral)
- Unaware of expectations
- Levels of Training/Expertise
- Lack of clarity in documentation needs
- Personnel habits/idiosyncracies
- Poor data management
- QA leading to corrective action too late to be meaningful
- Financial/Economic impact
- Willful (falsification/fraud/etc.)
- Time constraints/deadlines
- Others

### DATA INTEGRITY (hype!!!!)

- Media loves 'juicy' info to report
- D Integrity viewed in negative context/negative backdrop
- Two Agency independent inspections
   diagonally opposite findings
- Delineating 'unintentional error' and 'willful/intentional misconduct'
- Benefit of the doubt
- Innocent until proven guilty
- Element of *Subjective* versus *Objective* Assessment

### 

### We can -

- Discuss
- Debate
- Lecture on
- Speak about
- Present
- Webinars
- Etc.

till cows come home !!!.....

# **Foundation pillars of Integrity**

- Trust
- Communication
- Responsibility (Individual and Collective)

# Guiding Principle ....

## TRUST but VERIFY!!!!

### If You Find a Data Integrity Problem

- Disclose it to regulators
- Determine the scope
- Commit to voluntary remediation

FDA is much more willing to work with firms that voluntarily disclose and commit to fixing problems

### The 3P Mantra ....!!!!

- Proactive
- Prospective
- Pride of Possession/Ownership

### THANK YOU

DHANYAWAAD!!

धन्यवाद

umeshbanakar@juno.com

# Please ....

 Only easy/simple questions that I can answer !!!! Umesh V. Banakar, PhD

++ 317 440 7784 (mobile)

umeshbanakar@juno.com